Screening, diagnosis and prognosis of autism and other developmental disorders
View Patent ↗The invention provides a method and system combining functional genomic and genetic, proteomic, anatomic neuroimaging, functional neuroimaging, behavioral and clinical measurements and data analyses for autism pediatric population screening, diagnosis or prognosis. More specifically, the invention provides a weighted gene and feature test for autism which uses a weighted gene signature matrix for comparison to a reference database of healthy and afflicted individuals. The invention also provides normalized gene expression value signatures for comparison to a reference database. The invention additionally combines either the weighted gene or the normalized gene analysis with comparisons to a gene-networks signature matrix, a multi-modal signature matrix, and a collateral features signature matrix for improved accuracy in screening, diagnostic and prognostic relevance for autism, particularly for newborns, babies ages birth to 1 year, toddlers ages 1 to 2 years, toddlers ages 2 to 3 years and young children ages 3 through 4 years.
1. A method of conducting a weighted gene and feature test of autism (WGFTA) for autism screening, diagnosis or prognosis, comprising:
a) measuring gene expression levels for a subject for a group of genes consisting of at least 80 or more genes, wherein at least 20 or more genes are selected from each of the four gene sets listed in Tables 1.1 through 1.4 with absolute weight values ranging from about 0.50 to about 1.00 to form a set of raw gene expression data;
b) normalizing the gene expression level for each gene in the set of raw gene expression data to form a set of normalized gene expression data;
c) determining weighted gene expression levels for each gene in the set of normalized gene expression data using gene-specific weights from a reference autism weighted gene signature matrix (WGSM) to generate a set of weighted gene expression data, wherein the gene-specific weights are adjusted based on an age of the subject; and
d) determining for the subject a risk, diagnosis, or prognosis of autism by comparing a divergence of the set of weighted gene expression data to reference gene expression data from the reference autism WGSM.
2. The method of claim 1 , wherein the reference autism weighted gene signature matrix (WGSM) is derived from gene expression data from at least 40 healthy individuals and 40 autistic individuals.
3. The method of claim 1 , wherein the at least 20 or more genes are involved in cell cycle, protein folding, cell adhesion, translation, DNA damage response, apoptosis, immune/inflammation functions, signal transduction ESR1-nuclear pathway, transcription-mRNA processing, cell cycle meiosis, cell cycle G2-M, cell cycle mitosis, cytoskeleton-spindle microtubule, and cytoskeleton-cytoplasmic microtubule functions.
4. The method of claim 1 , wherein the determining for the subject the risk, diagnosis, or prognosis of autism further comprises comparing a divergence of a gene-network signature matrix (GNSM) of the subject to a reference autism GNSM wherein each said GNSM comprises interaction patterns of specific gene-weights and features calculated from gene-to-gene interactions, and wherein said interaction patterns are calculated based on the relationship or state of a gene with non-genomic features.
5. The method of claim 1 , wherein the determining for the subject the risk, diagnosis, or prognosis of autism further comprises comparing a divergence of a multi-modal signature matrix (MMSM) of the subject to a reference autism MMSM wherein each said MMSM contains a quantification of non-genomic features obtained by clinical, behavioral, anatomical, and functional measurements.
6. The method of claim 5 , wherein said non-genomic features comprise age, a GeoPreference test, a MRI test, a fMRI test, a DTI test, an Autism Diagnostic Observation Schedule (ADOS) test, or a Communication and Symbolic Behavior Scales (CSBS) test.
7. The method of claim 6 , wherein said non-genomic feature is age.
8. The method of claim 1 , wherein the determining for the subject the risk, diagnosis, or prognosis of autism further comprises comparing a divergence of a collateral feature signature matrix (CFSM) of the subject to a reference autism CFSM, wherein each said CFSM comprises analytes in maternal blood during pregnancy, a sibling with autism, or maternal genomic signature or preconditions.
9. The method of claim 1 , wherein the group of genes consists of at least 160 or more genes, wherein at least 40 or more genes are selected from each of the four gene sets listed in Tables 1.1 through 1.4.
10. The method of claim 1 , wherein the group of genes consists of up to 200 genes, wherein 50 genes are selected from each of the four gene sets listed in Tables 1.1 through 1.4.